Balchem Corp (BCPC) — ESG & Values Scores

Environment story

Balchem discloses limited environmental metrics and no comprehensive Scope 1, 2, or 3 emissions data. No net-zero target year is disclosed. The company faces significant regulatory scrutiny around ethylene oxide (EtO) emissions and usage, with EPA re-registration requiring phased compliance through 2035. Capital expenditures (~$40-45M annually) support facility improvements but lack explicit decarbonization focus. No renewable energy percentage disclosed. Supply chain and operational risks from climate change acknowledged but mitigation strategies unspecified. Absence of formal net-zero commitment and emissions transparency results in substantial deduction.

Criticisms on file

Ethylene Oxide (EtO) Regulatory Scrutiny — EPA IRIS Assessment & Re-Registration. EPA issued Interim Decision in January 2025 requiring phased compliance through 2035 for medical device sterilization and spice/seasoning applications. Company customers face reduced access to EtO sterilization; ongoing emissions monitoring and mitigation measures imposed. Company identified EtO as critical product with material adverse risk if EPA discontinues use.
Source: BCPC 10-K, Risk Factors and MD&A (EtO emissions and EPA IRIS Assessment)
Propylene Oxide (PO) Re-Registration Risk — Similar EPA regulatory pathway to EtO; progressing through multi-year FIFRA re-registration review. Future EPA determination to discontinue PO use disclosed as material adverse risk.
Source: BCPC 10-K, Item 1A Risk Factors (FIFRA re-registration process)
Supply Chain & Climate Disruption Risk — Company discloses exposure to supply chain disruptions from geopolitical conflict, natural disasters, and extreme weather. No quantified mitigation strategy or climate resilience planning disclosed.
Source: BCPC 10-K, Risk Factors (Global climate change, supply chain disruption)
Manufacturing Facility Risk — Operational risks including equipment failure, power outages, explosions, fires, natural disasters, and failure to maintain environmental standards disclosed. Specific environmental liabilities or remediation costs not quantified in filing.
Source: BCPC 10-K, Item 1A Risk Factors (Manufacturing facilities)

Disclosed initiatives

Capital Expenditure Program

Annual capex of $40-45M directed toward facility improvements and manufacturing enhancements across all production facilities

Supports operational resilience but lacks explicit decarbonization or renewable energy targets
Facility Compliance & Safety Standards

Ongoing compliance with environmental and health & safety regulations; focus on maintaining quality and safety standards

Reactive compliance rather than proactive climate leadership

Social story

Balchem demonstrates moderate social performance with unionized workforce cooperation but limited diversity and executive-compensation transparency. CEO-to-median-worker pay ratio not disclosed; union presence at North American and Italian facilities noted as stable with no recent major labor disputes documented. Leadership diversity metrics (executive/board women and URG %) not disclosed in filing. Workforce turnover and safety statistics unavailable. Supply chain human-rights audits not referenced. Company acknowledges reliance on workforce recruitment and retention in competitive labor market but provides no quantified diversity targets, pay-equity commitments, or supply-chain ethics policies.

Criticisms on file

Labor Relation Risk — Company discloses risk that unionized North American workforce and Italian facilities could strike or initiate work stoppages if collective-bargaining agreements cannot be renewed on 'reasonable terms.' No specific labor disputes or NLRB complaints documented in current filing, but forward-looking risk acknowledged.
Source: BCPC 10-K, Item 1A Risk Factors (Labor relations)
Executive Compensation Opacity — CEO-to-median-worker pay ratio not disclosed in filing. Executive/board diversity metrics absent. No pay-equity commitment, gender pay-gap analysis, or racial pay-gap disclosure provided.
Source: BCPC 10-K (Absence of compensation and diversity disclosures)
Supply Chain Human Rights & Ethics — No documented supply-chain ethics policy, conflict minerals policy, forced-labor statement, or living-wage commitment disclosed. Company identifies raw materials sourcing from outside U.S. but does not address labor conditions or human-rights vetting.
Source: BCPC 10-K, Risk Factors (Raw material sourcing and supply chain)

Disclosed initiatives

Workforce Recruitment & Retention

Company acknowledges need to recruit and retain highly qualified personnel across R&D, engineering, sales, manufacturing, IT, cybersecurity, accounting, and management. Recognizes labor shortages and competition for skilled employees as operational risks.

Reactive talent management; no proactive DEI or compensation equity programs disclosed
Union Cooperation Agreements

Maintains collective-bargaining agreements with North American unionized workforce and national bargaining coverage in Italy

Stable labor relations but no union-representation growth targets disclosed
Cybersecurity & Employee Training

Robust cybersecurity employee education program focused on email, password security, phishing recognition

Addresses operational risk but not social equity or worker well-being

Governance story

Balchem exhibits solid governance fundamentals with single-class share structure and no major active antitrust or fraud proceedings disclosed. Board independence percentage not disclosed in filing, preventing full assessment against 75% threshold. Lobbying expenditures and political spending not disclosed; unable to quantify lobbying directed at environmental deregulation. Anti-dumping duties imposed by EU (July 2025) on Chinese choline chloride imports represent trade/regulatory action but not evidence of company-directed lobbying. No shareholder litigation or climate proposal blocking actions disclosed. Overall governance posture appears compliant but lacks full transparency on board composition, political spending, and anti-ESG advocacy positioning.

Criticisms on file

Board Independence Disclosure Gap — Filing does not disclose board independence percentage, preventing verification against 75% threshold. Board composition, committee structure, and independence metrics absent from 10-K.
Source: BCPC 10-K (Absence of board composition and independence disclosures)
Political Spending & Lobbying Opacity — No annual lobbying expenditure or PAC contribution disclosures provided. Unable to assess whether company engages in lobbying designed to weaken climate regulation or environmental protections. Risk factor acknowledges 'anti-ESG legislative initiatives' but company stance on these initiatives not disclosed.
Source: BCPC 10-K, Item 1A Risk Factors (ESG and regulatory matters); absence of political spending disclosures
EU Anti-Dumping Duties on Choline Chloride Imports — European Commission imposed provisional duties of 95.4-120.8% (July 2025) and final duties of 90.0-115.9% (December 2025) on Chinese choline chloride following complaint by Balchem Italia Srl. Company was active complainant in EU trade investigation, resulting in material tariff impact on competitive market structure. Not evidence of company misconduct but demonstrates trade advocacy role.
Source: BCPC 10-K MD&A, Recent Developments (Anti-Dumping Investigation in the European Union)
Potential Regulatory Proceedings — Company acknowledges exposure to environmental liability, product recalls, and regulatory penalties but discloses no active proceedings. EtO and PO re-registration processes represent ongoing regulatory engagement with material business impact.
Source: BCPC 10-K, Item 1A Risk Factors (Regulatory risks, environmental liability, product liability)

Disclosed initiatives

Compliance & Disclosure Controls

Company implements disclosure controls, procedures, and internal controls over financial reporting required for public company compliance. References periodic reassessment of critical accounting estimates and GAAP adherence.

Standard corporate governance practice
Risk Management & Cybersecurity Governance

Board-level cybersecurity risk oversight; investment in IT systems infrastructure and third-party vendor management

Addresses operational and reputational risk
Regulatory Compliance Programs

Company maintains compliance structures for anti-corruption, export/import, anti-trust, data privacy, and AI governance due to global operations

Reactive compliance framework

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Balchem Corp. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Balchem Corp in the app for interactive charts and portfolio building.

More in Basic Materials

Linde plc (LIN) Southern Copper Corporation (SCCO) Newmont Corporation (NEM) Freeport-McMoRan Inc. (FCX) The Sherwin-Williams Company (SHW) Ecolab Inc. (ECL)